Secondary Logo

Institutional members access full text with Ovid®

Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors

Sise, Meghan E.a; Strohbehn, Ian A.b; Bethea, Emilyb; Gustafson, Jenna L.b; Chung, Raymond T.b

Current Opinion in Organ Transplantation: April 16, 2019 - Volume Publish Ahead of Print - Issue - p
doi: 10.1097/MOT.0000000000000651
REVIEW: PDF Only
Buy
PAP

Purpose of review Owing to long waitlist times and high waitlist morbidity and mortality, strategies to increase utilization of hepatitis C viremic-deceased donor organs are under investigation in kidney, liver, heart, and lung transplantation.

Recent findings Direct-acting antiviral medications for hepatitis C virus infection have high cure rates and are well tolerated. Small, single-center trials in kidney and heart transplant recipients have demonstrated that with early posttransplant direct-acting antiviral therapy, 100% of uninfected recipients of hepatitis C viremic organs have been cured of infection after transplantation.

Summary In this manuscript, we review the risks and rewards of utilizing hepatitis C viremic organs for transplantation.

aDepartment of Medicine, Division of Nephrology

bDepartment of Medicine, Liver Center, Gastrointestinal Division, Massachusetts General Hospital, Boston, Massachusetts, USA

Correspondence to Raymond T. Chung, Gastrointestinal Unit, Massachusetts General Hospital, 55 Fruit Street, Blake 4, Boston, MA 02114, USA. E-mail: rtchung@partners.org

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.